Citations

Clear

4847 citation(s) found for "Yu, Eric".

Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.
Jacobson, Caron A. , Jacobsen, Eric D. , Lekakis, Lazaros J. , Braunschweig, Ira , Oluwole, Olalekan O. , Deol, Abhinav , Bot, Adrian , Jiang, Yizhou , Rossi, John M. , Xue, Allen , Go, William Y., Neelapu, Sattva S. , Oluwole, Olalekan O , Locke, Frederick L. , Ghobadi, Armin , Miklos, David B. , Lin, Yi , Siddiqi, Tanya , Reagan, Patrick Michael , Farooq, Umar

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3003-3003

10.1200/jco.2018.36.15_suppl.3003 Get It

Expanding BRCA1/2 testing criteria to include other confirmed breast and ovarian cancer susceptibility genes.
Dolinsky, Jill S. , Yussuf, Amal , Hoang, Lily , Lilyquist, Jenna , Speare, Virginia , LaDuca, Holly , Couch, Fergus J. , Shimelis, Hermela , Polley, Eric C. , Horton, Carolyn , Hu, Chunling , Hart, Steven N.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 1524-1524

10.1200/jco.2018.36.15_suppl.1524 Get It

Low vs high dose carfilzomib (Cfz) with dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Results of SWOG S1304.
Sexton, Rachael, Lentzsch, Suzanne , Voorhees, Peter M. , Rohren, Eric , Kelly, Kevin R. , Mackler, Niklas J., Baer, David, Hoering, Antje , Durie, Brian G.M. , Ailawadhi, Sikander , Abidi, Muneer H. , Cohen, Adam D. , Heitner, Stephen B. , Orlowski, Robert Z.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8015-8015

10.1200/jco.2018.36.15_suppl.8015 Get It

A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG Z5041 trial (Alliance).
Wolff, Robert A. , Kindler, Hedy L. , Evans, Douglas B. , Misdraji, Joseph , Tamm, Eric P. , Sahani, Dushyant V., Moore, Malcolm J. , Newman, Elliot , Merchant, Nipun B. , Goff, Laura W. , Pisters, Peter W. T., Posner, Mitchell C. , (Alliance), ACOSOG, Wei, Alice C. , Ou, Fang‐Shu , Shi, Qian , O’Reilly, Eileen M. , Meyerhardt, Jeffrey A. , Deshpande, Vikram , Berlin, Jordan D. , (Alliance), ACOSOG

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4112-4112

10.1200/jco.2018.36.15_suppl.4112 Get It

Clinical outcomes in patients with baseline renal dysfunction in the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors.
Wolin, Edward M. , Chasen, Beth, Kulke, Matthew H. , Caplin, Martyn , Baum, Richard P. , Hobday, Timothy J. , Hendifar, Andrew , Ravasi, Laura, Öberg, Kjell E., Ruszniewski, Philippe, Krenning, Eric P. , Strosberg, Jonathan , Bushnell, David

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4102-4102

10.1200/jco.2018.36.15_suppl.4102 Get It

First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors.
Wolin, Edward M. , Chasen, Beth, Kulke, Matthew H. , Caplin, Martyn , Baum, Richard P. , Hobday, Timothy J. , Hendifar, Andrew , Sierra, Maribel Lopera , Öberg, Kjell E., Ruszniewski, Philippe, Krenning, Eric P. , Strosberg, Jonathan , Bushnell, David

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4099-4099

10.1200/jco.2018.36.15_suppl.4099 Get It

Association of sex and adverse events (AEs) of adjuvant chemotherapy (ACT) in early stage colon cancer (CC): A pooled analysis of 28,636 patients (pts) in the ACCENT database.
Haller, Daniel G. , Allegra, Carmen J. , VanCutsem, Eric, Gramont, Aimery de , Twelves, Chris, Blanke, Charles D. , Francini, Guido, Goldberg, Richard M. , Wagner, Dorothea , Grothey, Axel , André, Thierry , Dixon, Jesse G. , Wolmark, Norman , George, Thomas J. , Alberts, Steven R. , O’Connell, Michael J. , Saltz, Leonard B. , Kerr, Rachel , Yothers, Greg , Shi, Qian

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3603-3603

10.1200/jco.2018.36.15_suppl.3603 Get It

Radiosurgery and immune checkpoint inhibition in the treatment of brain metastases: A meta-analysis of patient-level data.
Lehrer, Eric J. , Peterson, Jennifer , Brown, Paul D. , Sheehan, Jason P. , Quiñones‐Hinojosa, Alfredo , Zaorsky, Nicholas G. , Trifiletti, Daniel M.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e14009-e14009

10.1200/jco.2018.36.15_suppl.e14009 Get It

Breast cancer cell-free DNA (cfDNA) profiles reflect underlying tumor biology: The Circulating Cell-Free Genome Atlas (CCGA) study.
Liu, Minetta C. , Maddala, Tara, Aravanis, Alex, Beausang, John F., Filippova, Darya , Gross, Samuel, Jamshidi, Arash , Shen, Ling , Valouev, Anton, Venn, Oliver, Smith, David A. , Curtis, Christina , Williams, Richard T. , Hartman, Anne‐Renee , Baselga, José, Aravanis, Alexander M. , Hubbell, Earl , Gross, Samuel, Kurtzman, Kathryn N. , Zhang, Nan , Couch, Fergus J. , Klein, Eric A.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 536-536

10.1200/jco.2018.36.15_suppl.536 Get It

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
Rhee, Frits van , Voorhees, Peter M. , Srkalović, Gordan , Ide, Makoto , Munshi, Nikhil C. , Schey, Stephen, Streetly, Matthew , Pierson, Sheila K. , Partridge, Helen , Shilling, Dustin, Stone, Katie , Greenway, Amy D, Ruth, Jason R., Lechowicz, Mary Jo , Jayanthan, Raj , Leitch, Heather A. , Pemmaraju, Naveen , Chadburn, Amy , Lim, Megan S. , Elenitoba‐Johnson, Kojo S.J. , Goodman, Aaron M. , Hoffmann, Christian , Zinzani, Pier Luigi , Ferrero, Simone , Terriou, Louis , Simpson, David , Rossi, Jean‐François, Yoshizaki, Kazuyuki , Oksenhendler, Éric , van Rhee, Frits , Wong, Raymond S M , Casper, Corey , Fajgenbaum, David C , Ferrero, Simone , Zinzani, Pier Luigi , Dispenzieri, Angela , Fosså, Alexander , Partridge, Helen L., Mukherjee, Sudipto , Chandrakasan, Shanmuganathan , Jaffe, Elaine S. , Krymskaya, Vera P. , Sato, Yasuharu , Wong, Raymond , Rossi, Jean‐François , Nasta, Sunita , Kurzrock, Razelle , Uldrick, Thomas S. , Casper, Corey , Fajgenbaum, David C. , Ide, Makoto , Lim, Megan S

Mayo Clinic

Blood | September 4, 2018 | Volume: 132 | Issue: 20 | Pages: 2115-2124

10.1182/blood-2018-07-862334 | PMID 30181172 Get It

Abstract Castleman disease (CD) describes a group of heterogeneous hematologic disorders with characteristic histopathological features. CD can present with unicentric or multicentric (MCD) regions of lymph node enlargement. Some cases of MCD are caused by human herpesvirus-8 (HHV-8), whereas others are HHV-8–negative/idiopathic (iMCD). Treatment of iMCD is challenging, and outcomes can be poor because no uniform treatment guidelines exist, few systematic studies have been conducted, and no agreed upon response criteria have been described. The purpose of this paper is to establish consensus, evidence-based treatment guidelines based on the severity of iMCD to improve outcomes. An international Working Group of 42 experts from 10 countries was convened by the Castleman Disease Collaborative Network to establish consensus guidelines for the management of iMCD based on published literature, review of treatment effectiveness for 344 cases, and expert opinion. The anti–interleukin-6 monoclonal antibody siltuximab (or tocilizumab, if siltuximab is not available) with or without corticosteroids is the preferred first-line therapy for iMCD. In the most severe cases, adjuvant combination chemotherapy is recommended. Additional agents are recommended, tailored by disease severity, as second- and third-line therapies for treatment failures. Response criteria were formulated to facilitate the evaluation of treatment failure or success. These guidelines should help treating physicians to stratify patients based on disease severity in order to select the best available therapeutic option. An international registry for patients with CD (ACCELERATE, #NCT02817997) was established in October 2016 to collect patient outcomes to increase the evidence base for selection of therapies in the future.